These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 24164086)

  • 61. Design and synthesis of 4-[(s-triazin-2-ylamino)methyl]-N-(2-aminophenyl)-benzamides and their analogues as a novel class of histone deacetylase inhibitors.
    Paquin I; Raeppel S; Leit S; Gaudette F; Zhou N; Moradei O; Saavedra O; Bernstein N; Raeppel F; Bouchain G; Fréchette S; Woo SH; Vaisburg A; Fournel M; Kalita A; Robert MF; Lu A; Trachy-Bourget MC; Yan PT; Liu J; Rahil J; MacLeod AR; Besterman JM; Li Z; Delorme D
    Bioorg Med Chem Lett; 2008 Feb; 18(3):1067-71. PubMed ID: 18160287
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Targeting NAMPT for Therapeutic Intervention in Cancer and Inflammation: Structure-Based Drug Design and Biological Screening.
    Pulla VK; Sriram DS; Soni V; Viswanadha S; Sriram D; Yogeeswari P
    Chem Biol Drug Des; 2015 Oct; 86(4):881-94. PubMed ID: 25850461
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility.
    Zak M; Liederer BM; Sampath D; Yuen PW; Bair KW; Baumeister T; Buckmelter AJ; Clodfelter KH; Cheng E; Crocker L; Fu B; Han B; Li G; Ho YC; Lin J; Liu X; Ly J; O'Brien T; Reynolds DJ; Skelton N; Smith CC; Tay S; Wang W; Wang Z; Xiao Y; Zhang L; Zhao G; Zheng X; Dragovich PS
    Bioorg Med Chem Lett; 2015 Feb; 25(3):529-41. PubMed ID: 25556090
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Synthesis and structure-activity relationship of new nicotinamide phosphoribosyltransferase inhibitors with antitumor activity on solid and haematological cancer.
    Fratta S; Biniecka P; Moreno-Vargas AJ; Carmona AT; Nahimana A; Duchosal MA; Piacente F; Bruzzone S; Caffa I; Nencioni A; Robina I
    Eur J Med Chem; 2023 Mar; 250():115170. PubMed ID: 36787658
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Allosteric inhibitors of Akt1 and Akt2: a naphthyridinone with efficacy in an A2780 tumor xenograft model.
    Bilodeau MT; Balitza AE; Hoffman JM; Manley PJ; Barnett SF; Defeo-Jones D; Haskell K; Jones RE; Leander K; Robinson RG; Smith AM; Huber HE; Hartman GD
    Bioorg Med Chem Lett; 2008 Jun; 18(11):3178-82. PubMed ID: 18479914
    [TBL] [Abstract][Full Text] [Related]  

  • 66. A preclinical study on the rescue of normal tissue by nicotinic acid in high-dose treatment with APO866, a specific nicotinamide phosphoribosyltransferase inhibitor.
    Olesen UH; Thougaard AV; Jensen PB; Sehested M
    Mol Cancer Ther; 2010 Jun; 9(6):1609-17. PubMed ID: 20515945
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Synthesis and Anticancer Activity of Novel Actinonin Derivatives as HsPDF Inhibitors.
    Hu L; Cai X; Dong S; Zhen Y; Hu J; Wang S; Jiang J; Huang J; Han Y; Qian Y; Yuan Y; Hu W
    J Med Chem; 2020 Jul; 63(13):6959-6978. PubMed ID: 32551649
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Synthesis and antitumor activity of novel diaryl ether hydroxamic acids derivatives as potential HDAC inhibitors.
    Zhu Y; Chen X; Wu Z; Zheng Y; Chen Y; Tang W; Lu T
    Arch Pharm Res; 2012 Oct; 35(10):1723-32. PubMed ID: 23139122
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDc-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer.
    Cai X; Zhai HX; Wang J; Forrester J; Qu H; Yin L; Lai CJ; Bao R; Qian C
    J Med Chem; 2010 Mar; 53(5):2000-9. PubMed ID: 20143778
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Design and campaign synthesis of piperidine- and thiazole-based histone deacetylase inhibitors.
    Andrews DM; Stokes ES; Carr GR; Matusiak ZS; Roberts CA; Waring MJ; Brady MC; Chresta CM; East SJ
    Bioorg Med Chem Lett; 2008 Apr; 18(8):2580-4. PubMed ID: 18378449
    [TBL] [Abstract][Full Text] [Related]  

  • 71. New class of azaheptapyridine FPT inhibitors as potential cancer therapy agents.
    Zhu HY; Desai J; Cooper AB; Wang J; Rane DF; Kirschmeier P; Strickland C; Liu M; Nomeir AA; Girijavallabhan VM
    Bioorg Med Chem Lett; 2014 Feb; 24(4):1228-31. PubMed ID: 24462667
    [TBL] [Abstract][Full Text] [Related]  

  • 72. N-hydroxy-3-phenyl-2-propenamides as novel inhibitors of human histone deacetylase with in vivo antitumor activity: discovery of (2E)-N-hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2-propenamide (NVP-LAQ824).
    Remiszewski SW; Sambucetti LC; Bair KW; Bontempo J; Cesarz D; Chandramouli N; Chen R; Cheung M; Cornell-Kennon S; Dean K; Diamantidis G; France D; Green MA; Howell KL; Kashi R; Kwon P; Lassota P; Martin MS; Mou Y; Perez LB; Sharma S; Smith T; Sorensen E; Taplin F; Trogani N; Versace R; Walker H; Weltchek-Engler S; Wood A; Wu A; Atadja P
    J Med Chem; 2003 Oct; 46(21):4609-24. PubMed ID: 14521422
    [TBL] [Abstract][Full Text] [Related]  

  • 73. 2-Substituted aminopyrido[2,3-d]pyrimidin-7(8H)-ones. structure-activity relationships against selected tyrosine kinases and in vitro and in vivo anticancer activity.
    Klutchko SR; Hamby JM; Boschelli DH; Wu Z; Kraker AJ; Amar AM; Hartl BG; Shen C; Klohs WD; Steinkampf RW; Driscoll DL; Nelson JM; Elliott WL; Roberts BJ; Stoner CL; Vincent PW; Dykes DJ; Panek RL; Lu GH; Major TC; Dahring TK; Hallak H; Bradford LA; Showalter HD; Doherty AM
    J Med Chem; 1998 Aug; 41(17):3276-92. PubMed ID: 9703473
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Design of new topoisomerase II inhibitors based upon a quinobenzoxazine self-assembly model.
    Zeng Q; Kwok Y; Kerwin SM; Mangold G; Hurley LH
    J Med Chem; 1998 Oct; 41(22):4273-8. PubMed ID: 9784102
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Synthesis and evaluation of 6-methylene-bridged uracil derivatives. Part 1: discovery of novel orally active inhibitors of human thymidine phosphorylase.
    Yano S; Kazuno H; Suzuki N; Emura T; Wierzba K; Yamashita J; Tada Y; Yamada Y; Fukushima M; Asao T
    Bioorg Med Chem; 2004 Jul; 12(13):3431-41. PubMed ID: 15186829
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Fragment-based discovery of a potent NAMPT inhibitor.
    Korepanova A; Longenecker KL; Pratt SD; Panchal SC; Clark RF; Lake M; Gopalakrishnan SM; Raich D; Sun C; Petros AM
    Bioorg Med Chem Lett; 2018 Feb; 28(3):437-440. PubMed ID: 29287958
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Synthesis of rigid trichostatin A analogs as HDAC inhibitors.
    Charrier C; Bertrand P; Gesson JP; Roche J
    Bioorg Med Chem Lett; 2006 Oct; 16(20):5339-44. PubMed ID: 16904890
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Design, synthesis and preliminary biological evaluation of new hydroxamate histone deacetylase inhibitors as potential antileukemic agents.
    Guandalini L; Cellai C; Laurenzana A; Scapecchi S; Paoletti F; Romanelli MN
    Bioorg Med Chem Lett; 2008 Sep; 18(18):5071-4. PubMed ID: 18723349
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Preclinical models of nicotinamide phosphoribosyltransferase inhibitor-mediated hematotoxicity and mitigation by co-treatment with nicotinic acid.
    Tarrant JM; Dhawan P; Singh J; Zabka TS; Clarke E; DosSantos G; Dragovich PS; Sampath D; Lin T; McCray B; La N; Nguyen T; Kauss A; Dambach D; Misner DL; Diaz D; Uppal H
    Toxicol Mech Methods; 2015 Mar; 25(3):201-11. PubMed ID: 25894564
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Identification of potent pyrazolo[4,3-h]quinazoline-3-carboxamides as multi-cyclin-dependent kinase inhibitors.
    Traquandi G; Ciomei M; Ballinari D; Casale E; Colombo N; Croci V; Fiorentini F; Isacchi A; Longo A; Mercurio C; Panzeri A; Pastori W; Pevarello P; Volpi D; Roussel P; Vulpetti A; Brasca MG
    J Med Chem; 2010 Mar; 53(5):2171-87. PubMed ID: 20141146
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.